What is Candel Therapeutics, Inc.'s (CADL) StockRank?

MoatMap's StockRank for Candel Therapeutics, Inc. (CADL) is 58/100, with a Hold signal. This is a composite score combining Quality (34), Value (36), and Momentum (77) factor ranks across MoatMap's 19,000+ stock universe.

Does Candel Therapeutics, Inc. have an economic moat?

Candel Therapeutics, Inc. (CADL) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Candel Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Candel Therapeutics, Inc. (CADL) is Hold, based on a StockRank of 58/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Candel Therapeutics, Inc. in?

Candel Therapeutics, Inc. (CADL) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CADL

HOLDREMOVE

Candel Therapeutics, Inc. · Healthcare · United States · $593M · Avg Vol: $18M/d

StockRank

P/E (TTM)

—

ROE

-51.2%

D/E

0.4x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Candel Therapeutics is a highly speculative, clinical-stage biotech company with low quality metrics and no current revenues, failing our Terry Smith quality filter.

COMPANY DESCRIPTION

Candel Therapeutics, Inc. is a clinical-stage biotechnology company developing oncolytic viral immunotherapies for the treatment of various cancers. The company leverages a proprietary oncolytic viral platform designed to selectively destroy cancer cells and stimulate systemic anti-tumor immunity. Candel Therapeutics operates as a niche player in the immuno-oncology space, pursuing novel approaches for difficult-to-treat malignancies.

FINANCIAL SUMMARY

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	125,000	0	0	0	—
EPS	-1.91	-0.65	-1.31	-1.74	—	—
Shares	—	29M	29M	47M	55M	+89.5%
Debt	—	23M	23M	13M	49M	29.1%
Equity	—	48M	13M	66M	52M	2.9%
Op CF	—	-31M	-34M	-27M	-38M	—
Inv CF	—	-1M	-280,000	-16,000	-560,000	—
Fin CF	—	20M	-121,000	94M	56M	—

PRICE (1M)+13.7%

SMA 50SMA 200

$8.56

RSI (14)

59.1

52W High

$9.57

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

-31.0%22.4

ROE

-51.2%17.0

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-30.3%9.4

Piotroski

—28.8

Int. Cover

-17.0x20.6

D/E Ratio

0.36x39.0

Current Ratio

28.05x97.6

Value

P/E (TTM)

—N/A

EV/EBITDA

-8.7x79.8

P/FCF

—N/A

P/B

4.5x26.8

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

89%88.1

RS 6M

24%88.8

SMA 50/200

1.25x92.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+122%77.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$593M

P/E (Forward)

38.9x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CADL are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CADL	Candel Therapeutics, Inc.(you)	$593M	58	HOLD
TECX	Tectonic Therapeutic, Inc.	$562M	56	HOLD
RLMD	Relmada Therapeutics, Inc.	$760M	59	HOLD
MDXG	MiMedx Group, Inc.	$547M	65	BUY
IPSC	Century Therapeutics, Inc.	$430M	55	HOLD
MGTX	MeiraGTx Holdings plc	$926M	59	HOLD
IMMX	Immix Biopharma, Inc.	$629M	48	HOLD
CLYM	Climb Bio, Inc.	$649M	46	HOLD
OMER	Omeros Corporation	$807M	50	HOLD
ANRO	Alto Neuroscience, Inc.	$710M	47	HOLD

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Candel Therapeutics, Inc. (CADL) — Stock Score Summary

Candel Therapeutics, Inc. (CADL) has a MoatMap StockRank of 58/100 based on Quality (34/100), Value (36/100), and Momentum (77/100) factor scores. The current signal is HOLD. Candel Therapeutics is a highly speculative, clinical-stage biotech company with low quality metrics and no current revenues, failing our Terry Smith quality filter.

Key Financial Metrics

Price	$8.56
Market Cap	$593M
P/E (Forward)	38.91
Price/Book	4.54
Return on Equity	-51.2%
Return on Invested Capital	-31.0%
Debt/Equity	35.70
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-38M

Candel Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Candel Therapeutics, Inc.’s (CADL) StockRank?: MoatMap’s StockRank for Candel Therapeutics, Inc. (CADL) is 58/100, with a Hold signal. It is a composite of Quality (34), Value (36), and Momentum (77) factor ranks across MoatMap’s 19,000+ stock universe.
Does Candel Therapeutics, Inc. have an economic moat?: Candel Therapeutics, Inc. (CADL) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Candel Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Candel Therapeutics, Inc. (CADL) is Hold, based on a StockRank of 58/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Candel Therapeutics, Inc. in?: Candel Therapeutics, Inc. (CADL) operates in the Healthcare sector, specifically the Biotechnology industry (United States).